Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients With Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-03
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 400
- Registration Number
- NCT00006103
S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach
- Conditions
- Interventions
- First Posted Date
- 2003-08-25
- Last Posted Date
- 2011-07-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 65
- Registration Number
- NCT00004233
- Locations
- 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy
- Conditions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00066846
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- UNICANCER
- Registration Number
- NCT00066274
- Locations
- 🇫🇷
Centre Regional Francois Baclesse, Caen, France
🇫🇷Centre Eugene Marquis, Rennes, France
🇫🇷Centre Antoine Lacassagne, Nice, France
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer
- Conditions
- First Posted Date
- 2003-08-05
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00026273
- Locations
- 🇫🇷
Hopital Tenon, Paris, France
🇦🇹Allgemeines Krankenhaus der Stadt Wien, Vienna (Wien), Austria
🇩🇪Universitats-Krankenhaus Eppendorf, Hamburg, Germany
Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
- Conditions
- First Posted Date
- 2003-07-18
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT00065117
- Locations
- 🇺🇸
Research Site, Pittsburgh, Pennsylvania, United States
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 86
- Registration Number
- NCT00064181
- Locations
- 🇪🇬
National Cancer Institute - Cairo, Cairo, Egypt
🇭🇺National Institute of Oncology, Budapest, Hungary
🇩🇪Westpfalz-Klinikum GmbH, Kaiserslautern, Germany
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
- Conditions
- Adenocarcinoma of the EsophagusMixed Adenocarcinoma of the StomachRecurrent Esophageal CancerStage IIIA Gastric CancerStage IV Esophageal CancerAdenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachRecurrent Gastric CancerSquamous Cell Carcinoma of the EsophagusStage III Esophageal Cancer
- Interventions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00064259
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
- Conditions
- First Posted Date
- 2003-07-08
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 6000
- Registration Number
- NCT00002582
- Locations
- 🇬🇧
Cancer Research Campaign Trials Unit-Birmingham (CRCTU), Birmingham, England, United Kingdom
🇬🇧Beatson Oncology Centre, Glasgow, Scotland, United Kingdom
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT00026364
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.